The Relationship Between Maternal Opioid Agonists and Psychiatric Medications on Length of Hospitalization for Neonatal Abstinence Syndrome
- 1 December 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 5 (4) , 293-299
Abstract
Objective: To examine the relationship between maternal opioid agonists, methadone, or buprenorphine (BPH), and concurrent psychiatric medication use on length of hospitalization (LOS) among infants with neonatal abstinence syndrome (NAS). Methods: We reviewed the charts of infants born at Boston Medical Center between 2003 and 2009 with a diagnosis of NAS whose mothers were prescribed methadone or BPH for opiate addiction. Univariate and multivariate linear regression analyses were used to examine associations between maternal opioid substitution concurrent with psychiatric medication use and infant LOS. We also tested whether exposure to BPH was associated with a shorter hospitalization. Results: A total of 273 mother-infant pairs were identified. The average LOS for all infants was 22.9 days (SD: 10.9). In bivariate analyses, maternal use of any psychiatric medication was associated with a longer infant LOS (P < 0.005). Compared with those prescribed methadone alone (n = 158), those also taking benzodiazepines (n = 56) had a 5.88-day longer LOS (95% confidence interval [CI]: 2.15–9.60, P = 0.002). Infants of mothers taking methadone plus an selective serotonin re-uptake inhibitor (n = 51) had a longer LOS (β = 4.47, 95% CI: 1.15–7.79) compared to methadone alone; results remained significant in an initial multivariate model, however the effect was attenuated when additional psychiatric medication use was added to the model. Compared with those exposed to methadone, those exposed to BPH (n = 22) had a significantly shorter LOS (ß = −7.35, CI: −0.18 to −14.52, P = 0.04). Conclusions: Maternal use of prescribed methadone and benzodiazepines, compared to methadone alone, increased LOS for infants with NAS by 6 days. Maternal use of BPH was associated with a shorter LOS.Keywords
This publication has 32 references indexed in Scilit:
- Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resourcesBJOG: An International Journal of Obstetrics & Gynaecology, 2009
- Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadonePharmacy World & Science, 2007
- Management of neonatal abstinence syndrome in neonates born to opioid maintained womenDrug and Alcohol Dependence, 2007
- Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndromeJournal of Perinatal Medicine, 2007
- Mood disorders affect drug treatment success of drug-dependent pregnant womenJournal of Substance Abuse Treatment, 2007
- Methadone versus buprenorphine in pregnant addicts: a double‐blind, double‐dummy comparison studyAddiction, 2006
- Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studiesPharmacoepidemiology and Drug Safety, 2005
- Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposureDrug and Alcohol Dependence, 2004
- Maternal methadone dose and neonatal withdrawalAmerican Journal of Obstetrics and Gynecology, 2003
- A Multicentre Prospective Controlled Study to Determine the Safety of Trazodone and Nefazodone Use during PregnancyThe Canadian Journal of Psychiatry, 2003